Protein & Therapeutic Antibody Development

Take the guesswork out of therapeutic antibody development with just 5 µL of sample. From late-stage discovery to manufacturing QC, the Aura family of particle analyzers delivers fast and more accurate insights, providing you with the data points you need to make smarter decisions.


Discover what Aura can do and experience the difference with proven results.

Stability Matters

We all know the promise that CHO cells hold when it comes to therapeutic antibody development: scalability, high protein titers, and manufacturing potential. Yet, little has been done to characterize the physical stability of secreted antibodies from their inception during CHO cell line development, which leaves you with one option: stabilizing biologics that were not designed with aggregation in mind from the ground up.

For the first time, Aura immunoassays with particle characterization bridge the gap between cell line development and developability to allow pre-screening for antibody stability once mAbs are secreted from CHO cells. Characterization is fast, accurate, and detailed—no more lengthy analysis or prolonged wait times to get the data you need.

Measure Stability, Don’t Just Predict It

Have you been searching for an all-in-one protein aggregation and characterization particle analysis tool that includes advanced formulation characterization? With Aura, now you’ve found it.

Unlike products that simply use protein degradation metrics such as Tm to predict stability, our technology takes it one step further by measuring actual aggregation for stability, providing far more reliable insight into the product quality of your therapeutic antibody. With Aura, now you can truly understand the impact of proper biologics formulation on product stability.

Innovating For Biologics Developers

The Particle Mask and FMM: (a) Brightfield particle mask characterizes entire particle distribution (size and counts). Black regions denote no particles measured; white regions denote measured particles in BMI. (b) FMM conducted after fluorescently labeling particles in a protein/non-protein mix.

“...Backgrounded Membrane Imaging (BMI)...low volume option for particle characterization while providing significantly increased sensitivity compared to classical particle characterization methods such as light obscuration.” – Merck